Affinity Biosensors announced that George Goedesky has joined its team as Vice President of Sales and Marketing. He will lead the rollout of the LifeScale AST system for rapid antibiotic susceptibility tests, now in U.S. clinical trials for identifying targeted therapy for sepsis. George has extensive experience introducing ground-breaking diagnostic technologies that have achieved wide adoption and significant impact on patient care. Most recently, he led the adoption of the Bruker MALDI Biotyper (MBT) platform in the Americas.
Ken Babcock, CEO of Affinity Biosensors, commented:
“We are thrilled to have George leading the introduction of LifeScale AST in the U.S. clinical microbiology market. He brings an exemplary track record of success, a deep understanding of the clinical utility of new diagnostics, and extensive contacts with leading microbiologists and hospitals. Most of all, it’s George’s passion for improving patient care by introducing game-changing technologies that make him a perfect fit with our effort to revolutionize rapid susceptibility testing with LifeScale AST.”
George Goedesky commented:
“I am very excited to be joining the Affinity Biosensors team. Their deep expertise in mass sensing technologies has resulted in a product (Lifescale AST) which can assist in the fight against emerging antibiotic resistance. Lifescale AST offers laboratories the fastest phenotypic AST and does so with a platform that is both cost effective and operationally efficient. I look forward to working with the microbiology community on evaluating and implementing this exciting new product.”